Keisaku Sato, Fanyin Meng, Gianfranco Alpini – 26 March 2019

Johns Shaji Mathew, K.Y. Santosh Kumar, Krishnanunni Nair, Binoj Sivasankara Pillai Thankamony Amma, Lakshmi Krishnakumar, Dinesh Balakrishnan, Unnikrishnan Gopalakrishnan, Ramachandran Narayana Menon, Aleena Sunny, Puneet Dhar, Sudheer Othiyil Vayoth, Sudhindran Surendran – 25 March 2019 – Traditionally, deceased donor liver grafts receive dual perfusion (DP) through the portal vein and the hepatic artery (HA) either in situ or on the back table. HA perfusion is avoided in living donor liver grafts for fear of damage to the intima and consequent risk of hepatic artery thrombosis (HAT).

Jeffrey M. Mah, Yvonne DeWit, Maya Djerboua, Alexandre Menard, Christopher M. Booth, Jennifer A. Flemming – 25 March 2019 – Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure designed to treat portal hypertension. Hospital teaching status is an institutional factor found to be predictive of outcomes following several complex procedures; however, its impact on outcomes following TIPS is unknown. The aim of this study was to determine the association between hospital teaching status and long‐term survival in patients with cirrhosis receiving TIPS.

Sehee Kim, Jeffrey Moore, Estella Alonso, Joseph Bednarek, Jorge A. Bezerra, Catherine Goodhue, Saul J. Karpen, Kathleen M. Loomes, John C. Magee, Vicky L. Ng, Averell H. Sherker, Caroline Smith, Cathie Spino, Veena Venkat, Kasper Wang, Ronald J. Sokol, Cara L. Mack, The Childhood Liver Disease Research Network – 25 March 2019 – Biliary atresia is a progressive fibroinflammatory cholangiopathy of infancy that is associated with activation of innate and adaptive immune responses targeting bile ducts.

Yanyong Xu, Yingdong Zhu, Kavita Jadhav, Yuanyuan Li, Huihui Sun, Liya Yin, Takhar Kasumov, Xiaoli Chen, Yanqiao Zhang – 25 March 2019 – Hepatocytes are the major source of hepatic lipocalin‐2 (LCN2), which is up‐regulated in response to inflammation, injury, or metabolic stress. So far, the role of hepatocyte‐derived LCN2 in the development of nonalcoholic fatty liver disease (NAFLD) remains unknown.

Jie Yang, Eric Trépo, Pierre Nahon, Qian Cao, Christophe Moreno, Eric Letouzé, Sandrine Imbeaud, Quentin Bayard, Thierry Gustot, Jacques Deviere, Paulette Bioulac‐Sage, Julien Calderaro, Nathalie Ganne‐Carrié, Alexis Laurent, Jean Frédéric Blanc, Erwan Guyot, Angela Sutton, Marianne Ziol, Jessica Zucman‐Rossi, Jean‐Charles Nault – 25 March 2019 – Recently, a loss of function variant (rs72613567) in 17‐beta‐hydroxysteroid dehydrogenase 13 (HSD17B13) has been identified as protective of nonalcoholic (NAFLD) and alcoholic liver disease (ALD).

Cindy Piao, Norah A. Terrault, Souvik Sarkar – 25 March 2019 – Healthcare delivery has been dramatically changing in recent times with advances in technology. One area of expansion has been the use of telemedicine due to progression in communication technologies. Telemedicine offers the opportunity to overcome barriers of access, improve patient satisfaction, improve healthcare outcomes and streamline communication between patients and providers.

Alexander Y. Pan, Lauren D. Feld, Jeanne M. Farnan, Steven K. Herrine, Adam E. Mikolajczyk – 25 March 2019

Florence Wong, K. Rajender Reddy, Jacqueline G. O’Leary, Puneeta Tandon, Scott W. Biggins, Guadalupe Garcia‐Tsao, Benedict J. Maliakkal, Jennifer C. Lai, Michael B. Fallon, Hugo E. Vargas, Ram Subramanian, Paul J. Thuluvath, Patrick S. Kamath, Leroy Thacker, Jasmohan S. Bajaj – 25 March 2019 – We hypothesize that the prevalence of chronic kidney disease (CKD) among patients with cirrhosis has increased due to the increased prevalence of CKD‐associated comorbidities, such as diabetes.

Vinay Sundaram, Parth Shah, Robert J. Wong, Constantine J. Karvellas, Brett E. Fortune, Nadim Mahmud, Alexander Kuo, Rajiv Jalan – 25 March 2019 – Patients listed for liver transplantation (LT) as status 1a currently receive the highest priority on the waiting list. The presence of acute on chronic liver failure (ACLF) with three or more organs failing (ACLF‐3) portends low survival without transplantation, which may not be reflected by the Model for End‐Stage Liver Disease‐Sodium (MELD‐Na) score.